NEMERA acquired by LGT CAPITAL PARTNERS
Context
The deal represents a strategic investment by LGT Capital Partners, Montagu, and Astorg in Nemera, a leading global manufacturer of complex drug delivery devices. The transaction is expected to support Nemera's future growth plans, including enhancing its portfolio, expanding manufacturing capacity, and investing in innovation and operational excellence to meet rising global demand. The investment is closely aligned with the firms' focus on being leading global providers of capital solutions for private equity fund managers and their portfolio companies. With the support of its existing shareholders and the addition of LGT Capital Partners, Nemera is well-positioned to accelerate its growth trajectory and continue to scale globally, providing advanced solutions to its partners and patients worldwide. The deal demonstrates the confidence of the investors in Nemera's strategy and management team, and their commitment to supporting the company's next phase of development. The transaction is expected to have a positive impact on the market, as it will enable Nemera to further strengthen its position in the drug delivery devices market and expand its global footprint.
In the past, the company had already been the subject of several LBOs, notably led by Montagu Private Equity in 2014 and Astorg in 2018. This succession of buyouts highlights the strong attractiveness of the company's business model.
NEMERA, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
REFERENCES
Revenue range: 450M - 900M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEMERA by LGT CAPITAL PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: nemera
Acquirer: lgt capital partners